Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 2
2011 1
2012 11
2013 33
2014 70
2015 262
2016 597
2017 1045
2018 1299
2019 1564
2020 1792
2021 1816
2022 1609
2023 1421
2024 527

Text availability

Article attribute

Article type

Publication date

Search Results

10,618 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab Plus Relatlimab: First Approval.
Paik J. Paik J. Drugs. 2022 Jun;82(8):925-931. doi: 10.1007/s40265-022-01723-1. Drugs. 2022. PMID: 35543970 Review.
Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag()) is a fixed-dose, combination immunotherapy treatment being developed by Bristol Myers Squibb for the treatment of multiple types of advanced cancers. ...In March 2022, nivolumab plus relatl …
Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag()) is a fixed-dose, combination immunotherapy treatment bei …
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benítez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A. Provencio M, et al. N Engl J Med. 2023 Aug 10;389(6):504-513. doi: 10.1056/NEJMoa2215530. Epub 2023 Jun 28. N Engl J Med. 2023. PMID: 37379158 Clinical Trial.
METHODS: In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery. Patients in …
METHODS: In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant …
Nivolumab for the treatment of hepatocellular carcinoma.
Chiew Woon L, Joycelyn Jie Xin L, Su Pin C. Chiew Woon L, et al. Expert Opin Biol Ther. 2020 Jul;20(7):687-693. doi: 10.1080/14712598.2020.1749593. Epub 2020 Apr 20. Expert Opin Biol Ther. 2020. PMID: 32249635 Review.
In recent years, many other treatment options have received approval for advanced HCC, including nivolumab, a Programmed-Death-1 (PD-1) inhibitor. AREAS COVERED: We review the current treatment landscape of HCC, an overview of the characteristics of nivolumab and cu …
In recent years, many other treatment options have received approval for advanced HCC, including nivolumab, a Programmed-Death-1 (PD- …
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
Albrecht LJ, Livingstone E, Zimmer L, Schadendorf D. Albrecht LJ, et al. Curr Oncol Rep. 2023 Jun;25(6):647-657. doi: 10.1007/s11912-023-01406-4. Epub 2023 Apr 1. Curr Oncol Rep. 2023. PMID: 37004702 Free PMC article. Review.
RECENT FINDINGS: Relatlimab, a LAG-3 blocking antibody, was investigated in combination with nivolumab in a phase 2/3 randomized double-blind trial (RELATIVITY-047) and could demonstrate significantly improved progression-free survival in treatment-naive advanced melanoma …
RECENT FINDINGS: Relatlimab, a LAG-3 blocking antibody, was investigated in combination with nivolumab in a phase 2/3 randomized doub …
Nivolumab for the treatment of colorectal cancer.
Smith KM, Desai J. Smith KM, et al. Expert Rev Anticancer Ther. 2018 Jul;18(7):611-618. doi: 10.1080/14737140.2018.1480942. Epub 2018 Jun 11. Expert Rev Anticancer Ther. 2018. PMID: 29792730 Review.
Areas covered: Nivolumab gained regulatory approval for the treatment of dMMR/MSI-H metastatic colorectal cancer in mid 2017. The current review will summarize the clinical evidence of checkpoint inhibitors in metastatic colorectal cancer, with a focus on nivolumab. …
Areas covered: Nivolumab gained regulatory approval for the treatment of dMMR/MSI-H metastatic colorectal cancer in mid 2017. The cur …
Nivolumab for the treatment of hepatocellular carcinoma.
Finkelmeier F, Waidmann O, Trojan J. Finkelmeier F, et al. Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175. doi: 10.1080/14737140.2018.1535315. Epub 2018 Oct 22. Expert Rev Anticancer Ther. 2018. PMID: 30304963 Review.
In September 2017, nivolumab was approved by the FDA for liver cancer as a second line treatment after failure of sorafenib based on the data of the multi-cohort phase 1/2 trial CheckMate-040. ...Randomized phase III trials of nivolumab, pembrolizumab, atezolizumab, …
In September 2017, nivolumab was approved by the FDA for liver cancer as a second line treatment after failure of sorafenib based on …
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.
Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry MB, Ross-Macdonald P, Wind-Rotolo M. Motzer RJ, et al. J Immunother Cancer. 2022 Mar;10(3):e004316. doi: 10.1136/jitc-2021-004316. J Immunother Cancer. 2022. PMID: 35304405 Free PMC article.
BACKGROUND: The phase 3 CheckMate 214 trial demonstrated higher response rates and improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line therapy for advanced clear-cell renal cell carcinoma (RCC). ...RESULTS: Biomarkers previously associat …
BACKGROUND: The phase 3 CheckMate 214 trial demonstrated higher response rates and improved overall survival with nivolumab plus ipil …
Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.
Liu P, Pan X, Chen C, Niu T, Shuai X, Wang J, Chen X, Liu J, Guo Y, Xie L, Wu Y, Liu Y, Liu T. Liu P, et al. Blood. 2020 Mar 12;135(11):826-833. doi: 10.1182/blood.2019003886. Blood. 2020. PMID: 31914172 Free article.
Here, we performed a retrospective analysis of 7 r/r EBV-HLH patients who were treated with nivolumab on a compassionate-use basis at West China Hospital. All 7 patients tolerated the treatment and 6 responded to it. ...Our data suggest that nivolumab, as a monother …
Here, we performed a retrospective analysis of 7 r/r EBV-HLH patients who were treated with nivolumab on a compassionate-use basis at …
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ, Hutson T, Zhang J, Zoco J, Johansen JL, Rezazadeh Kalebasty A. Tykodi SS, et al. J Immunother Cancer. 2022 Feb;10(2):e003844. doi: 10.1136/jitc-2021-003844. J Immunother Cancer. 2022. PMID: 35210307 Free PMC article. Clinical Trial.
METHODS: Patients with previously untreated advanced/metastatic nccRCC, Karnofsky performance status 70%, and any International Metastatic Renal Cell Carcinoma Database Consortium risk received up to four doses of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks fol …
METHODS: Patients with previously untreated advanced/metastatic nccRCC, Karnofsky performance status 70%, and any International Metastatic R …
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu HY, Wu L, Feng J, Zhang Y, Luft AV, Zhou J, Ma Z, Lu Y, Hu C, Shi Y, Baudelet C, Cai J, Chang J. Wu YL, et al. J Thorac Oncol. 2019 May;14(5):867-875. doi: 10.1016/j.jtho.2019.01.006. Epub 2019 Jan 17. J Thorac Oncol. 2019. PMID: 30659987 Free article. Clinical Trial.
Objective response rate was 17% with nivolumab versus 4% with docetaxel; median duration of response was not reached versus 5.3 months. ...In this population with previously treated advanced NSCLC, nivolumab improved OS versus docetaxel. Results were consistent with …
Objective response rate was 17% with nivolumab versus 4% with docetaxel; median duration of response was not reached versus 5.3 month …
10,618 results
You have reached the last available page of results. Please see the User Guide for more information.